- Acting as a liaison between industry and the Stem Cell institute to promote industrial application of the insights gained in the lab- Providing support for intellectual property management: acquisition of licenses, ensuring freedom to operate, filing patent applications, material transfer agreements.- Business opportunity plan development- Project management, grant application, execution, reporting, and presentation of accomplishments- Coordination of the KU Leuven Stem Cell Core Facility• people management of a team of seven people• recruitment of two new colleagues (ranking of candidates, interviews)• promotion of the capabilities of the Core Facility• supervising the activity of the Core Facility (generation of human induced pluripotent stem cells, genome editing of human induced pluripotent stem cells)• implementation of new methods in the Core Facility• organizing and teaching stem cell courses- Coordination of the installation of an automated stem cell culture platform (NextGenQBio Hercules application)

- Development of assays for detecting phenotypic differences between neuronal cells differentiated from human induced pluripotent stem cell (hiPSC) lines derived from patients with neurodegenerative disease and those derived from healthy individuals- Generation of the first transgenic hiPSCs using CRISPR/Cas9 technology at the company

- Development human embryonic stem cell (hESC)-based model for p53 aggregation

http://www.switchlab.org/

I studied intracellular protein quality control, endoplasmic reticulum-associated degradation, proteasomal degradation of two model proteins: alpha-1-antitrypsin and the cystic fibrosis transmembrane conductance regulator.